NCT07011589View on ClinicalTrials.gov

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2026

Conditions
Epidermolysis Bullosa (EB)Epidermolysis Bullosa AcquisitaRecessive Dystrophic Epidermolysis BullosaDystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

Efgartigimod

Dosage: 10mg/kg Frequency: Once a week Duration: 25 weeks

Trial Locations (1)

94163

Stanford University, Redwood City

Sponsors

Collaborators (1)

argenx
All Listed Sponsors
collaborator

argenx

INDUSTRY

lead

M. Peter Marinkovich

OTHER

NCT07011589 - Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) | Biotech Hunter | Biotech Hunter